FDA Launches New Program to Accelerate Meeting Minutes Clarifications

The U.S. Food and Drug Administration (FDA) has introduced a new pilot program aimed at enhancing…

Temporary Approval Issued for Selectol 200 mg Tablets in French Packaging

Swissmedic has issued a temporary authorization allowing the distribution of Selectol 200 mg film-coated tablets in…

Swissmedic Updates: New Measures to Address Suicide Risk with Finasteride and Dutasteride

On November 18, 2025, Swissmedic announced new measures to mitigate the risk of suicidal thoughts associated…

Swissmedic’s Multilingual Initiative: Vigilance-News Now Available in Four Languages

Swissmedic has announced an important update to its Vigilance-News publication, ensuring accessibility for a broader audience.…

Swissmedic Releases Haemovigilance Annual Report 2024 With Key Findings on Transfusion Safety

Swissmedic, the Swiss agency for therapeutic products, has published its Haemovigilance Annual Report for the year…

FDA Adds High-Profile Warning to Elevidys Label Amid Fatal Liver Injury Reports

The U.S. Food and Drug Administration (FDA) has approved a significant update to the labeling of…

FDA Issues Guidance on Unauthorized Anti-Choking Devices: Follow Proven Rescue Protocols

The Food and Drug Administration (FDA) has issued an important update encouraging the public to use…

Swissmedic Issues Recall for GlucoSaline B. Braun Infusion Solution Batch

Swissmedic has announced a recall of batch number 242867651 for the product GlucoSaline B. Braun Infusion…

Swissmedic Updates: Safety Revisions to Product Information Starting November 2025

Swissmedic has announced a significant update regarding the publication of safety-related revisions to product information. Effective…

Swissmedic Announces Initial Authorisation of ZYNYZ® – Key Updates for Industry Professionals

Swissmedic has granted the first authorisation for ZYNYZ®, marking a significant regulatory milestone. This development signals…